7
i
Abstract Under the globalization trend even the still growing industry of Taiwan Biopharmaceutical will meet the same developing rule Many of the Biotechnology or Pharmaceutical companies are not satisfied with the local market here in Taiwanthey are not only trying efforts to make efficiency of the limited resources of Taiwan itselfbut have had take China market into consideration during make company business plan There is no doubt that Taiwan s BioPharm insutry are moving their steps into mainland China, especially since 1990 when China slowly open the free market to the world capital Many of them have had achieved much success, yet many companies found difficulties and entry barriers much as well So farthere is still no any research or survey about how Taiwan BioPharmaceutical are doing in China? What were their strategy for the marketwhat are the facing problems or challenge in China? What are the solutions to cope with?...and so on In this thesisit content both field studycompany interview and questionnaire survey to gather the first hand data from industry that could picture the real situation about the Taiwan BioPharmaceutical companies in China so far Furthermore,by analyze the datait could get the conclusions and findings that help the industry realized what are main problems for the China market and what could be the most successful strategy,too It shows China is the future market for globe biopharmaceutical industry Taiwan companies need to build up the niche competency of its own selfyet there still are many problems come form uncertain China government policyregulation and market game rules to face with ii
SRI iii
iv
v
vi
vii
1-1
1-2
1-3
1-4
1-5
1-6
2-1
2-2
2-3
2-4
2-5
2-6
2-7
2-8
2-9
2-10
2-11
2-12
2-13
2-14
2-15
2-16
2-17
2-18
2-19
2-20
2-21
2-22
2-23
2-24
2-25
2-26
2-27
2-28
2-29
2-30
2-31
2-32
/ 1 2003 2 3 3-1
1 3-1 3-2
2 3-3
3-4
3-5 1975-1990
3-6
3-7
3-8
3-9
( ) 1 2003 2 3 4 ( 2002) 180 / () 3-5 3-10
3-11 3-4 84/03/22 84/03/29 84/04/21 84/04/14 84/04/20 84/04/20 84/04/21 84/04/21 83/06/10 84/06/13 84/04/22 84/04/27 84/04/07 6/28 84/06/07 7/18 84/05/07 84/04/13 7/9 84/04/13 84/03/07 7/11 84/04/14
1996 1995 3-12
() 3-4 3-13
( ) ( ) () 3-14
岀 3 3-15
4-1
4-2
4-3
4-4
4-5
4-6
4-7
: : : : CMO GLP cgmp : ccgm 4-8
SRI 4-9
4-10 Bridge Bridge SRI BPI BPI (2004.06 )
4-11
5-1
5-2
褀 5-3
5-4
5-5
5-6
5-7
5-8
5-9
5-10
5-11
5-12
5-13
5-14
5-15
5-16
5-17
5-18
组 5-19
5-20
5-21
5-22
5-23
5-24
5-25
5-26
5-27
5-28
5-29
5-30
5-31
5-32
産 5-33
5-34
5-35
5-36
5-37
閳 5-38
5-39
5-40
5-41
5-42
5-43
5-44
5-45
6-1
6-2
6-3
6-4
6-5
6-6
6-7
6-8
6-9
6-10
6-11
6-12
6-13
6-14
6-15
6-16
6-17
6-18
6-19
7-1
7-2
7-3
7-4
7-5
苷
肽
産 産 産 産 産